C-Cure is a bone marrow-derived stem cell therapy aimed at regenerating cardiac tissue following severe damage due to myocardial infarctions. C-Cure consists of a patient’s own cells harvested from bone marrow, which are treated with Celyad’s proprietary cell culture to form autologous heart muscle cells. These cells are then re-injected directly into the scar tissue of the patient’s heart to repopulate the damaged areas and improve cardiac function.
LIST OF FIGURES
8 Figure 1: C-Cure for chronic heart failure – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of C-Cure for chronic heart failure
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of C-Cure for chronic heart failure
12 Figure 4: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: C-Cure drug profile
6 Table 2: C-Cure’s proposed Phase III trial design in chronic heart failure
7 Table 3: C-Cure completed late-phase data in chronic heart failure
13 Table 4: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.